| Literature DB >> 12927511 |
Abstract
The majority of pharmaceutically relevant drug targets cluster into densely populated target families, thus offering a novel approach that complements the currently favoured screening paradigm in medicinal chemistry. This approach uses a privileged structure concept whereby molecular masterkeys are developed that account for a target family wide structural or functional commonality. Numerous lead compounds, based on multipurpose privileged structures, can be generated that address a variety of targets from a gene family of interest, irrespective of therapeutic area. Several different interpretations of the privileged structure concept will be highlighted, with a strong emphasis on the most stringent application: the optimization of a molecular masterkey for a distinct target family of interest.Mesh:
Year: 2003 PMID: 12927511 DOI: 10.1016/s1359-6446(03)02781-8
Source DB: PubMed Journal: Drug Discov Today ISSN: 1359-6446 Impact factor: 7.851